An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502361-15-00

Acronym

IM011-075

Enrollment

664

Registered

2024-04-05

Start date

2019-12-12

Completion date

2025-07-31

Last updated

2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate-to-Severe Plaque Psoriasis

Brief summary

Adverse events and serious adverse events

Detailed description

sPGA 0/1 response, PASI 75 response

Interventions

DRUGdeucravacitinib

DRUGPlacebo to match BMS 986165 tablet

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Adverse events and serious adverse events	—

Secondary

Measure	Time frame
sPGA 0/1 response, PASI 75 response	—

Countries

Czechia, Finland, France, Germany, Hungary, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026